ClinicalTrials.gg
CompletedNCT04081337Updated Feb 8, 2024Results posted

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

A Phase 1 interventional study of Tirzepatide and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
62nd of 104
55 · median 69
Started
2020
with 2 others
Phase 1
12 of 104
5 open now
Registered
1st of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 62nd largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have of 30 to 45 kilograms per square meter (kg/m²), inclusive
  • Have a stable body weight in the past 1 month prior to screening
  • Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff

Exclusion criteria

Exclusion Criteria:

  • Have undergone gastric bypass or bariatric surgery
  • Have a diagnosis of type 2 diabetes
  • Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data
  • Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening
  • Have any lifetime history of a suicide attempt
  • Patient Health Questionnaire-9 (PHQ-9) score of 15 or more at screening
  • Positive responses to selected items on the Columbia Suicide Severity Rating Scale (C-SSRS)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.

    Drug: Placebo

  • Experimental
    15 Milligram (mg) Tirzepatide

    Participants received 15 mg of tirzepatide QW by SC injection.

    Drug: Tirzepatide

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)

    SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

    Time frame: Baseline, Week 18

Secondary outcomes

  1. Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal

    Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  2. Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)

    24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

    Time frame: Baseline, Week 18

  3. Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)

    Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 \[Liter/24hour\] / total VO2 \[Liter/24hour\]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  4. Change From Baseline to Week 18 in Sleep RQ

    Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  5. Change From Baseline to Week 18 in Duration of Periods With RQ<0.80

    RQ\<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ \<0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  6. Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation

    Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented. * Protein Oxidation = 6.25\*\[urinary nitrogen\] * Fat Oxidation = 1.689\*\[total oxygen consumption (VO2)\] - 1.689\*\[total carbon dioxide production (VCO2)\] - 0.324\*\[protein oxidation\] * Carbohydrate Oxidation = 4.113\*\[VCO2\] - 2.907\*\[VO2\] - 0.375\*\[protein oxidation\]. Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  7. Change From Baseline to Week 18 in Body Weight (BW)

    Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

    Time frame: Baseline, Week 18

  8. Change From Baseline to Week 18 in Body Fat-Free Mass

    Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  9. Change From Baseline to Week 18 in Body Fat Mass

    Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  10. Change From Baseline to Week 18 in Percentage of Body Fat Mass

    The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  11. Change From Baseline to Week 18 in Lipid Metabolism Parameters

    Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  12. Change From Baseline to Week 18 in Fasting Insulin Resistance

    Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= \[Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)\] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18 during standardized mixed meal tolerance test

  13. Change From Baseline to Week 18 in Postprandial Insulin Sensitivity

    Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of \<2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  14. Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT

    Total AUC from time zero to 4 hours after start of the meal \[AUC0-4 hours\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

    Time frame: Baseline, Week 18

  15. Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)

    HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

    Time frame: Baseline, Week 18

07

Results

Posted Feb 8, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo15 Milligram (mg) Tirzepatide
Started2827
Received at least one dose of study drug2827
Completed2424
Not completed43
Withdrew: Adverse event01
Withdrew: Withdrawal by subject20
Withdrew: Physician decision12
Withdrew: Lost to follow-up10

Outcome measures

PrimaryChange From Baseline to Week 18 in Sleep Metabolic Rate (SMR)

SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · kilocalories per day (kcal/day)
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
kilocalories per day (kcal/day)Placebo15 mg Tirzepatide
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)-154.36 ± 19.69-134.68 ± 21.62
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.5733 · Ls mean difference: 19.68 · 95% CI -50.36 to 89.72
SecondaryChange From Baseline to Week 18 in Food Intake During Ad Libitum Meal

Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · kilocalories (kcal)
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal
kilocalories (kcal)Placebo15 mg Tirzepatide
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal-58.57 ± 82.29-914.51 ± 82.29
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.0001 · Ls mean difference: -855.94 · 95% CI -1090.87 to -621.02
SecondaryChange From Baseline to Week 18 in 24-hour Energy Expenditure (EE)

24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · kcal/day
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
kcal/dayPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)-296.85 ± 27.67-300.07 ± 30.44
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.9481 · Ls mean difference: -3.22 · 95% CI -102.65 to 96.20
SecondaryChange From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)

Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 \[Liter/24hour\] / total VO2 \[Liter/24hour\]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · Ratio
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
RatioPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)0.005 ± 0.005-0.030 ± 0.006
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.0001 · Ls mean difference: -0.034 · 95% CI -0.051 to -0.018
SecondaryChange From Baseline to Week 18 in Sleep RQ

Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · ratio
Change From Baseline to Week 18 in Sleep RQ
ratioPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Sleep RQ-0.001 ± 0.006-0,028 ± 0.006
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0031 · Ls mean difference: -0.028 · 95% CI -0.045 to -0.010
SecondaryChange From Baseline to Week 18 in Duration of Periods With RQ<0.80

RQ\<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ \<0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · minute
Change From Baseline to Week 18 in Duration of Periods With RQ<0.80
minutePlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Duration of Periods With RQ<0.802.55 ± 43.97254.44 ± 47.14
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0004 · Ls mean difference: 251.89 · 95% CI 119.09 to 384.69
SecondaryChange From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation

Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented. * Protein Oxidation = 6.25\*\[urinary nitrogen\] * Fat Oxidation = 1.689\*\[total oxygen consumption (VO2)\] - 1.689\*\[total carbon dioxide production (VCO2)\] - 0.324\*\[protein oxidation\] * Carbohydrate Oxidation = 4.113\*\[VCO2\] - 2.907\*\[VO2\] - 0.375\*\[protein oxidation\]. Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · gram/day
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
gram/dayPlacebo15 mg Tirzepatide
Adjusted protein oxidation-0.14 ± 1.23-7.00 ± 1.32
Adjusted fat oxidation-1.64 ± 2.1512.83 ± 2.30
Adjusted carbohydrate oxidation4.23 ± 4.24-22.42 ± 4.54
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0005 · Ls mean difference: -6.87 · 95% CI -10.51 to -3.22
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.0001 · Ls mean difference: 14.48 · 95% CI 8.02 to 20.93
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0001 · Ls mean difference: -26.64 · 95% CI -39.46 to -13.83
SecondaryChange From Baseline to Week 18 in Body Weight (BW)

Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline to Week 18 in Body Weight (BW)
kilogram (kg)Placebo15 mg Tirzepatide
Change From Baseline to Week 18 in Body Weight (BW)-8.26 ± 0.90-16.73 ± 0.92
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -8.47 · 95% CI -11.04 to -5.90
SecondaryChange From Baseline to Week 18 in Body Fat-Free Mass

Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · kg
Change From Baseline to Week 18 in Body Fat-Free Mass
kgPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Body Fat-Free Mass-1.64 ± 0.36-5.73 ± 0.36
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -4.08 · 95% CI -5.12 to -3.05
SecondaryChange From Baseline to Week 18 in Body Fat Mass

Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · kg
Change From Baseline to Week 18 in Body Fat Mass
kgPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Body Fat Mass-6.75 ± 0.65-11.83 ± 0.65
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.0001 · Ls mean difference: -5.08 · 95% CI -6.93 to -3.22
SecondaryChange From Baseline to Week 18 in Percentage of Body Fat Mass

The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · Percentage
Change From Baseline to Week 18 in Percentage of Body Fat Mass
PercentagePlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Percentage of Body Fat Mass-3.12 ± 0.36-4.26 ± 0.36
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0304 · Ls mean difference: -1.14 · 95% CI -2.16 to -0.11
SecondaryChange From Baseline to Week 18 in Lipid Metabolism Parameters

Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · millimole hour per liter (mmol.h/L)
Change From Baseline to Week 18 in Lipid Metabolism Parameters
millimole hour per liter (mmol.h/L)Placebo15 mg Tirzepatide
Triglyceride-0.69 ± 0.27-2.52 ± 0.27
VLDL cholesterol-0.32 ± 0.12-1.16 ± 0.12
HDL cholesterol0.20 ± 0.18-0.33 ± 0.18
Free fatty acid-0.09 ± 0.080.35 ± 0.08
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.0001 · Ls mean difference: -1.83 · 95% CI -2.60 to -1.06
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.0001 · Ls mean difference: -0.84 · 95% CI -1.19 to -0.48
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0436 · Ls mean difference: -0.53 · 95% CI -1.05 to -0.02
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0002 · Ls mean difference: 0.45 · 95% CI 0.23 to 0.66
SecondaryChange From Baseline to Week 18 in Fasting Insulin Resistance

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= \[Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)\] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18 during standardized mixed meal tolerance test
Reported as:
Least squares mean · index
Change From Baseline to Week 18 in Fasting Insulin Resistance
indexPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Fasting Insulin Resistance-0.37 ± 0.12-0.34 ± 0.14
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.8762 · Ls mean difference: 0.03 · 95% CI -0.34 to 0.40
SecondaryChange From Baseline to Week 18 in Postprandial Insulin Sensitivity

Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of \<2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · index
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity
indexPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity1.43 ± 0.944.92 ± 0.94
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0126 · Ls mean difference: 3.49 · 95% CI 0.79 to 6.19
SecondaryChange From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT

Total AUC from time zero to 4 hours after start of the meal \[AUC0-4 hours\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · millimolar.hour per liter (mmol.h/L)
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT
millimolar.hour per liter (mmol.h/L)Placebo15 mg Tirzepatide
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT-1.73 ± 0.38-3.00 ± 0.38
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = 0.0222 · Ls mean difference: -1.26 · 95% CI -2.34 to -0.19
SecondaryChange From Baseline to Week 18 in Hemoglobin A1c (HbA1c)

HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)
percentage of glycosylated hemoglobinPlacebo15 mg Tirzepatide
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)-0.04 ± 0.04-0.40 ± 0.04
Statistical analysis
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.0001 · Ls mean difference: -0.36 · 95% CI -0.48 to -0.23

Adverse events

Collected over Baseline Through End of Safety Follow-up (Up to 22 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/28 (0%)0/28 (0%)19/28 (67.9%)
15 mg Tirzepatide0/27 (0%)1/27 (3.7%)22/27 (81.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo15 mg Tirzepatide
PancreatitisGastrointestinal disorders0/281/27
CholelithiasisHepatobiliary disorders0/281/27
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlacebo15 mg Tirzepatide
NauseaGastrointestinal disorders7/2814/27
ConstipationGastrointestinal disorders4/2810/27
Injection site reactionGeneral disorders0/2810/27
HeadacheNervous system disorders9/286/27
VomitingGastrointestinal disorders3/287/27
DiarrhoeaGastrointestinal disorders2/286/27
DyspepsiaGastrointestinal disorders0/285/27
Corona virus infectionInfections and infestations4/281/27
Abdominal distensionGastrointestinal disorders1/283/27
Urinary tract infectionInfections and infestations3/282/27

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo15 mg TirzepatideTotal
Mean48.1 ± 10.745.5 ± 9.846.8 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo15 mg TirzepatideTotal
Female242246
Male459
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo15 mg TirzepatideTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American121123
White151429
More than one race123
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Placebo15 mg TirzepatideTotal
United States282755
08

Study locations

1 site
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2022, 22 months.

Results were first posted in Feb 2024, 1 year 8 months after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 22 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2019
First posted
Sep 9, 2019
StartActual
Jul 9, 2020
Primary completionActual
May 26, 2022
CompletionActual
May 26, 2022
Results first posted
Feb 8, 2024
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04081337
Responsible party
Sponsor
First posted
Sep 9, 2019
Start date
Jul 9, 2020
Primary completion
May 26, 2022
Completion
May 26, 2022
Results posted
Feb 8, 2024
Last update
Feb 8, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion